Search

This case report discusses a female patient with axial spondyloarthritis (AS) who developed inflammatory bowel disease (IBD) after being treated with secukinumab (SEC), an interleukin-17 inhibitor. The patient had a family history of AS and psoriasis, and her symptoms worsened after starting SEC treatment. She experienced upper abdominal pain, nausea, vomiting, and gastrointestinal bleeding. The report highlights the association between SEC and the exacerbation of gastrointestinal symptoms leading to IBD. It also mentions the low incidence rate of IBD in patients treated with SEC and the lack of reports on neurological damage associated with SEC use. [Extracted from the article]

Wilms' tumor (WT) is the most common pediatric renal malignancy. PDGFRβ belongs to the type III receptor tyrosine kinase family and is known to be involved in tumor metastasis and angiogenesis. Here, we studied the effect and underlying mechanism of PDGFRβ on WT G401 cells. Transwell assay and wound‐healing assay were used to detect the effect of PDGFRβ on G401 cells invasion and migration. Western blot and immunofluorescence were used to detect the expression of EMT‐related genes. The expression of PI3K/AKT/mTOR pathway proteins was detected by Western blot. The relationship between PDGFRβ and aerobic glycolysis was studied by assessing the expression of glycolysis‐related enzymes detected by qRT‐PCR and Western blot. The activity of HK, PK, and LDH was detected by corresponding enzyme activity kits. The concentration of lactic acid and glucose was detected by Lactic Acid Assay Kit and Glucose Assay Kit‐glucose oxidase method separately. To investigate the mechanism of PDGFRβ in the development of WT, the changes of glucose and lactic acid were analyzed after blocking PI3K pathway, aerobic glycolysis, or PDGFRβ. The key enzyme was screened by Western blot and glucose metabolism experiment after HK2, PKM2, and PDK1 were inhibited. The results showed that PDGFRβ promoted the EMT process by modulating aerobic glycolysis through PI3K/AKT/mTOR pathway in which PKM2 plays a key role. Therefore, our study of the mechanism of PDGFRβ in G401 cells provides a new target for the treatment of WT. [ABSTRACT FROM AUTHOR]